ArticleClinical epigenetics2018
Urine cell-based DNA methylation classifier for monitoring bladder cancer.
Article in Clinical epigenetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review.Current oncology (Toronto, Ont.) · 2024Pooled it
- Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review.BMC urology · 2020Pooled it
- Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.The Journal of clinical investigation · 2020Trial
- Review
- Urinary biomarkers in multicentric studies: Shaping the future of bladder cancer diagnosis and follow-up.BJUI compass · 2025Review
- Advancements in DNA methylation technologies and their application in cancer diagnosis.Epigenetics · 2025Review
- Unleashing the potential of urine DNA methylation detection: Advancements in biomarkers, clinical applications, and emerging technologies.Current urology · 2025Article
- Bisulfite-freeBioengineering & translational medicine · 2025Article
- Intervention of machine learning in bladder cancer research using multi-omics datasets: systematic review on biomarker identification.Discover oncology · 2025Review
- DNA Methylation in Urine and Feces Indicative of Eight Major Human Cancer Types Globally.Life (Basel, Switzerland) · 2025Review
- Hypermethylated TAGMe as a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma.Journal of translational medicine · 2024Article
- Advances in Liquid Biopsy for Diagnosis of Bladder Cancer.International neurourology journal · 2024Article
- CALN1 hypomethylation as a biomarker for high-risk bladder cancer.BMC urology · 2022Article
- Biomarkers of Bladder Cancer: Cell-Free DNA, Epigenetic Modifications and Non-Coding RNAs.International journal of molecular sciences · 2022Review
- The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know?International journal of environmental research and public health · 2022Review
- CancerNet: a unified deep learning network for pan-cancer diagnostics.BMC bioinformatics · 2022Article
- A novel and sensitive DNA methylation marker for the urine-based liquid biopsies to detect bladder cancer.BMC cancer · 2022Article
- SALL Proteins; Common and Antagonistic Roles in Cancer.Cancers · 2021Review
- Bioinformatics analysis to screen DNA methylation-driven genes for prognosis of patients with bladder cancer.Translational andrology and urology · 2021Article
- Tumoral markers in bladder cancer (Review).Experimental and therapeutic medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current standard methods used to detect and monitor bladder cancer (BC) are invasive or have low sensitivity. This study aimed to develop a urine methylation biomarker classifier for BC monitoring and validate this classifier in patients in follow-up for bladder cancer (PFBC). Methods: Voided urine samples ( Results: A three-gene methylation classifier containing Conclusions: The combination of the three-gene methylation classifier and cytology results has high sensitivity and high negative predictive value in a real clinical scenario (PFBC). The proposed classifier is a useful test for predicting BC recurrence and decrease the number of cystoscopies in the follow-up of BC patients. If only patients with a positive combined classifier result would be cystoscopied, 36% of all cystoscopies can be prevented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.